Month: April 2020

Hermed indkaldes til ekstraordinær generalforsamling i SmallCap Danmark A/S (CVR nr. 39703416) onsdag d. 20. maj 2020 kl. 10:00 hos Mazanti-Andersen Korsø Jensen Advokatpartnerselskab, Amaliegade 10, DK-1256 København K.Idet Coronavirus-situationen fortsætter med at udvikle sig, overvåger vi udviklingen nøje, herunder anbefalinger fra relevante sundhedsmyndigheder vedrørende store sammenkomster.Forudsat et forsamlingsforbud ikke umuliggør dette og en generalforsamling kan gennemføres på forsvarlig vis har bestyrelsen besluttet at afholde ekstraordinær general­forsamling med mulighed for fysisk fremmøde. Såfremt udviklingen umuliggør dette vil bestyrelsen søge at afholde generalforsamlingen elektronisk. Såfremt dette bliver nødvendigt vil yderligere information herom tilgå aktionærerne.Bestyrelsen henleder opmærksomheden på muligheden for...

VAUGHAN, Ontario, April 28, 2020 (GLOBE NEWSWIRE) — IGNITE International Brands, Ltd. (CSE:BILZ, OTCQX: BILZF) (“IGNITE” or the “Company”), a global consumer packaged goods brand, is ramping up efforts to help in the fight against the current coronavirus pandemic. Product donations and new COVID-19 response products have become priorities for the Company as it joins in the global effort to eradicate the virus.IGNITE’s new line of COVID-19 response products includes masks, gloves, hand sanitizer and sanitizing surface spray. To develop these products, IGNITE has partnered with LCF Labs. LCF Labs is in the business of contract manufacturing and packing for a growing number of customers with leading brands in the vape industry; however, partially as a result of its agreement with its partnership with IGNITE,...

SOUTH SAN FRANCISCO, Calif., April 28, 2020 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (NASDAQ: CBIO), a biopharmaceutical company developing novel subcutaneous (SQ) therapies for hemophilia and other bleeding disorders, today announced the European Patent Office has issued the Company a FIX portfolio patent covering the lead clinical candidate, dalcinonacog alfa (DalcA) for Factor IX (FIX) replacement therapy, and the Company’s FIX preclinical gene therapy candidate, CB 2679d-GT.“This newly issued EU patent expands the breadth of our Factor IX intellectual property portfolio. We now have broad patent coverage in all major markets including the United States, the European Union, Japan and China,” said Nassim Usman, Ph.D., Catalyst’s president and chief executive officer. “DalcA has successfully completed a Phase 2b clinical...

SAN DIEGO, April 28, 2020 (GLOBE NEWSWIRE) — Daré Bioscience, Inc.(NASDAQ: DARE), a leader in women’s health innovation, today announced that Sabrina Martucci Johnson, President and Chief Executive Officer, will participate in a panel discussion during the Infectious Disease Virtual Conference presented by Maxim Group on May 5, 2020. Ms. Johnson will be a member of the panel discussing non-antibiotic anti-infectives, scheduled from 10:30 a.m. to 12:00 p.m. Eastern Time.During the panel discussion, Ms. Johnson will share insights from the Company’s DARE-BV1 development program. DARE-BV1, a novel thermosetting bio-adhesive hydrogel formulated with clindamycin phosphate 2%, is an investigational product for the treatment of bacterial vaginosis (BV), one of the most common vaginal infections. The Company plans to initiate a Phase 3...

SANTA MONICA, Calif., April 28, 2020 (GLOBE NEWSWIRE) — Opiant Pharmaceuticals, Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced that it will report its financial results for the first quarter ended March 31, 2020, after the market close and host a corporate update conference call and webcast on Tuesday, May 12, at 4:30 p.m. Eastern Time.Conference Call Details:Tuesday, May 12th at 4:30 p.m. Eastern Time/1:30 p.m. Pacific TimeToll Free:                                877-407-0792International:                          201-689-8263Conference ID:                       13702897Webcast:                                http://public.viavid.com/index.php?id=139556About Opiant Pharmaceuticals, Inc.Opiant Pharmaceuticals, Inc., the company that...

The Company Easily Surpasses its Previous Monthly Record, of $14,607.91 in E-Commerce Sales, Posted During March 2020NEW YORK, NY, April 28, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a revenue generating Company that operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that its highest margin business segment (E-Commerce), continues to demonstrate meaningful levels of growth, momentum, and overall strength.  For the month of April 2020, the Company has already established a new monthly record – with respect to its E-Commerce sales.  The Company is confident that its existing fulfillment infrastructure can handle significant...

ALLENTOWN, PA, April 28, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE –American Energy Partners, Inc. (“American Energy”) (PINK: AEPT), a diversified energy company, is excited to announce that its wholly owned subsidiary Oilfield Basics is on track to meet its announced expansion of remote learning content.  The first suite of courses will be available beginning this summer. Derek Krieg, President of Oilfield Basics, noted that, “Oilfield Basics has seen a surge of interested professionals across our industry reach out to us wanting to share their knowledge with others across our incredible industry.” David Marks of Dominion Energy Field Services was one of the first to agree to contribute.  Mr. Marks is an energy commodities trading expert who specializes in Appalachian Basin futures.  Mr. Marks commented, “I am working diligently...

PHILADELPHIA and OXFORDSHIRE, United Kingdom, April 28, 2020 (GLOBE NEWSWIRE) — Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in cell therapy to treat cancer, announced that the European Medicine Agency’s (EMA) Committee for Orphan Medicinal Products (COMP) has adopted a positive opinion for Orphan Drug Designation for ADP-A2M4 for the treatment of soft tissue sarcomas.  Adaptimmune’s SPEARHEAD-1 trial with ADP-A2M4 for people with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS) is actively enrolling at approximately 25 clinical sites in Canada, France, Spain, the United Kingdom, and the US. The SPEARHEAD-1 trial is intended to support the registration of ADP‑A2M4 for the treatment of advanced synovial sarcoma and MRCLS.“Outcomes with currently available treatments remain unsatisfactory for patients with inoperable...